Tumor necrosis factor administration is associated with increased endogenous production of M-CSF and G-CSF but not GM-CSF in human cancer patients

Theodore Logan, W. Gooding, J. M. Kirkwood, R. K. Shadduck

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

In humans, tumor necrosis factor (TNF) treatment has been associated with characteristic changes in circulating white blood cell populations (leukopenia followed by leukocytosis) and increased cell-surface expression of integrins. A similar pattern of effects on leukocytes occurs with granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF treatment. To determine whether these effects were caused directly by TNF or as a result of secondary CSF release, G-, GM-, and M-CSF levels were measured after TNF infusion (9.6 x 106 U/mg protein; 2, days 1-5 every third week) and 10 patients (four colon cancer, four head and neck cancer; one melanoma; one sarcoma) received mitomycin C (15 mg/m2, day 1) followed by TNF (69-180 μg/m2 days 1-3) every sixth week. All treatments were given IV, mitomycin C over 5 minutes and TNF over 2 hours. Serum samples were collected at times 0 (before mitomycin C and TNF) and 1, 2, 4, 6, 12, and 24 hours after TNF initiation on day 1 and at similar times on subsequent treatment days. M-CSF samples were analyzed by radioimmunoassay. (RIA) and G-CSF and GM-CSF by ELISA. The mean baseline M-CSF levels in normal control subjects (n = 12) was 158.4 ± 36.2 (SD) U/mL, and in pretreatment cancer patients (n = 10) 235.7 ± 60.9 U/mL (p = 0.004, Wilcoxon test). M-CSF levels increased 4 hours after TNF initiation (mean 354.7 ± 96.3 U/mL; p = 0.020), remained elevated at 6 hours (305.6 ± 45.4 U/mL; p = 0.004, Wilcoxon signed-rank test), and subsequently,declined. This pattern was seen in all patients treated with TNF, whether treatment was TNF alone or TNF with mitomycin C. In patients treated with mitomycin C and TNF, GCSF levels increased at 4 hours after TNF initiation (mean 3886 ± 2009 pg/mL; p = 0.004), remained elevated at 6 hours (mean 2140 ± 1131 pg/ml; p = 0.004), and subsequently declined. GM-CSF levels were not measurable before or after treatment, with TNF. The changes in all three endogenous cytokines were not temporally related to the previously described leukopenia and integrin upregulation on circulating leukocytes and, there: fore, appear to be unrelated to this event. However, release of endogenous G-CSF and M-CSF under the influence of TNF does temporally coincide with the previously described leukocytosis, suggesting a possible role for these endogenous cytokines in the release of bone marrow cellular stores.

Original languageEnglish (US)
Pages (from-to)49-53
Number of pages5
JournalExperimental Hematology
Volume24
Issue number1
StatePublished - 1996
Externally publishedYes

Fingerprint

Macrophage Colony-Stimulating Factor
Granulocyte Colony-Stimulating Factor
Granulocyte-Macrophage Colony-Stimulating Factor
Tumor Necrosis Factor-alpha
Neoplasms
Mitomycin
Leukocytes
Leukocytosis
Leukopenia
Head and Neck Neoplasms
Integrins
Therapeutics
Cytokines
Nonparametric Statistics
Sarcoma
Colonic Neoplasms
Radioimmunoassay
Melanoma

Keywords

  • Cancer patients
  • Cytokine network
  • GM-CSF
  • M-CSF
  • TNF

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

Tumor necrosis factor administration is associated with increased endogenous production of M-CSF and G-CSF but not GM-CSF in human cancer patients. / Logan, Theodore; Gooding, W.; Kirkwood, J. M.; Shadduck, R. K.

In: Experimental Hematology, Vol. 24, No. 1, 1996, p. 49-53.

Research output: Contribution to journalArticle

@article{e127aabf79834bc8a7199ff1c7f7a85e,
title = "Tumor necrosis factor administration is associated with increased endogenous production of M-CSF and G-CSF but not GM-CSF in human cancer patients",
abstract = "In humans, tumor necrosis factor (TNF) treatment has been associated with characteristic changes in circulating white blood cell populations (leukopenia followed by leukocytosis) and increased cell-surface expression of integrins. A similar pattern of effects on leukocytes occurs with granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF treatment. To determine whether these effects were caused directly by TNF or as a result of secondary CSF release, G-, GM-, and M-CSF levels were measured after TNF infusion (9.6 x 106 U/mg protein; 2, days 1-5 every third week) and 10 patients (four colon cancer, four head and neck cancer; one melanoma; one sarcoma) received mitomycin C (15 mg/m2, day 1) followed by TNF (69-180 μg/m2 days 1-3) every sixth week. All treatments were given IV, mitomycin C over 5 minutes and TNF over 2 hours. Serum samples were collected at times 0 (before mitomycin C and TNF) and 1, 2, 4, 6, 12, and 24 hours after TNF initiation on day 1 and at similar times on subsequent treatment days. M-CSF samples were analyzed by radioimmunoassay. (RIA) and G-CSF and GM-CSF by ELISA. The mean baseline M-CSF levels in normal control subjects (n = 12) was 158.4 ± 36.2 (SD) U/mL, and in pretreatment cancer patients (n = 10) 235.7 ± 60.9 U/mL (p = 0.004, Wilcoxon test). M-CSF levels increased 4 hours after TNF initiation (mean 354.7 ± 96.3 U/mL; p = 0.020), remained elevated at 6 hours (305.6 ± 45.4 U/mL; p = 0.004, Wilcoxon signed-rank test), and subsequently,declined. This pattern was seen in all patients treated with TNF, whether treatment was TNF alone or TNF with mitomycin C. In patients treated with mitomycin C and TNF, GCSF levels increased at 4 hours after TNF initiation (mean 3886 ± 2009 pg/mL; p = 0.004), remained elevated at 6 hours (mean 2140 ± 1131 pg/ml; p = 0.004), and subsequently declined. GM-CSF levels were not measurable before or after treatment, with TNF. The changes in all three endogenous cytokines were not temporally related to the previously described leukopenia and integrin upregulation on circulating leukocytes and, there: fore, appear to be unrelated to this event. However, release of endogenous G-CSF and M-CSF under the influence of TNF does temporally coincide with the previously described leukocytosis, suggesting a possible role for these endogenous cytokines in the release of bone marrow cellular stores.",
keywords = "Cancer patients, Cytokine network, GM-CSF, M-CSF, TNF",
author = "Theodore Logan and W. Gooding and Kirkwood, {J. M.} and Shadduck, {R. K.}",
year = "1996",
language = "English (US)",
volume = "24",
pages = "49--53",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Tumor necrosis factor administration is associated with increased endogenous production of M-CSF and G-CSF but not GM-CSF in human cancer patients

AU - Logan, Theodore

AU - Gooding, W.

AU - Kirkwood, J. M.

AU - Shadduck, R. K.

PY - 1996

Y1 - 1996

N2 - In humans, tumor necrosis factor (TNF) treatment has been associated with characteristic changes in circulating white blood cell populations (leukopenia followed by leukocytosis) and increased cell-surface expression of integrins. A similar pattern of effects on leukocytes occurs with granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF treatment. To determine whether these effects were caused directly by TNF or as a result of secondary CSF release, G-, GM-, and M-CSF levels were measured after TNF infusion (9.6 x 106 U/mg protein; 2, days 1-5 every third week) and 10 patients (four colon cancer, four head and neck cancer; one melanoma; one sarcoma) received mitomycin C (15 mg/m2, day 1) followed by TNF (69-180 μg/m2 days 1-3) every sixth week. All treatments were given IV, mitomycin C over 5 minutes and TNF over 2 hours. Serum samples were collected at times 0 (before mitomycin C and TNF) and 1, 2, 4, 6, 12, and 24 hours after TNF initiation on day 1 and at similar times on subsequent treatment days. M-CSF samples were analyzed by radioimmunoassay. (RIA) and G-CSF and GM-CSF by ELISA. The mean baseline M-CSF levels in normal control subjects (n = 12) was 158.4 ± 36.2 (SD) U/mL, and in pretreatment cancer patients (n = 10) 235.7 ± 60.9 U/mL (p = 0.004, Wilcoxon test). M-CSF levels increased 4 hours after TNF initiation (mean 354.7 ± 96.3 U/mL; p = 0.020), remained elevated at 6 hours (305.6 ± 45.4 U/mL; p = 0.004, Wilcoxon signed-rank test), and subsequently,declined. This pattern was seen in all patients treated with TNF, whether treatment was TNF alone or TNF with mitomycin C. In patients treated with mitomycin C and TNF, GCSF levels increased at 4 hours after TNF initiation (mean 3886 ± 2009 pg/mL; p = 0.004), remained elevated at 6 hours (mean 2140 ± 1131 pg/ml; p = 0.004), and subsequently declined. GM-CSF levels were not measurable before or after treatment, with TNF. The changes in all three endogenous cytokines were not temporally related to the previously described leukopenia and integrin upregulation on circulating leukocytes and, there: fore, appear to be unrelated to this event. However, release of endogenous G-CSF and M-CSF under the influence of TNF does temporally coincide with the previously described leukocytosis, suggesting a possible role for these endogenous cytokines in the release of bone marrow cellular stores.

AB - In humans, tumor necrosis factor (TNF) treatment has been associated with characteristic changes in circulating white blood cell populations (leukopenia followed by leukocytosis) and increased cell-surface expression of integrins. A similar pattern of effects on leukocytes occurs with granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF treatment. To determine whether these effects were caused directly by TNF or as a result of secondary CSF release, G-, GM-, and M-CSF levels were measured after TNF infusion (9.6 x 106 U/mg protein; 2, days 1-5 every third week) and 10 patients (four colon cancer, four head and neck cancer; one melanoma; one sarcoma) received mitomycin C (15 mg/m2, day 1) followed by TNF (69-180 μg/m2 days 1-3) every sixth week. All treatments were given IV, mitomycin C over 5 minutes and TNF over 2 hours. Serum samples were collected at times 0 (before mitomycin C and TNF) and 1, 2, 4, 6, 12, and 24 hours after TNF initiation on day 1 and at similar times on subsequent treatment days. M-CSF samples were analyzed by radioimmunoassay. (RIA) and G-CSF and GM-CSF by ELISA. The mean baseline M-CSF levels in normal control subjects (n = 12) was 158.4 ± 36.2 (SD) U/mL, and in pretreatment cancer patients (n = 10) 235.7 ± 60.9 U/mL (p = 0.004, Wilcoxon test). M-CSF levels increased 4 hours after TNF initiation (mean 354.7 ± 96.3 U/mL; p = 0.020), remained elevated at 6 hours (305.6 ± 45.4 U/mL; p = 0.004, Wilcoxon signed-rank test), and subsequently,declined. This pattern was seen in all patients treated with TNF, whether treatment was TNF alone or TNF with mitomycin C. In patients treated with mitomycin C and TNF, GCSF levels increased at 4 hours after TNF initiation (mean 3886 ± 2009 pg/mL; p = 0.004), remained elevated at 6 hours (mean 2140 ± 1131 pg/ml; p = 0.004), and subsequently declined. GM-CSF levels were not measurable before or after treatment, with TNF. The changes in all three endogenous cytokines were not temporally related to the previously described leukopenia and integrin upregulation on circulating leukocytes and, there: fore, appear to be unrelated to this event. However, release of endogenous G-CSF and M-CSF under the influence of TNF does temporally coincide with the previously described leukocytosis, suggesting a possible role for these endogenous cytokines in the release of bone marrow cellular stores.

KW - Cancer patients

KW - Cytokine network

KW - GM-CSF

KW - M-CSF

KW - TNF

UR - http://www.scopus.com/inward/record.url?scp=0030032055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030032055&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 49

EP - 53

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 1

ER -